NHS medicine shortage: what medicines are affected?
Pharmacists warn of delays and price increases for commonly prescribed drugs
Pharmacists have warned that many common medicines are becoming increasingly hard to supply, leaving patients facing delays and “vastly increased prices”.
Widely used painkillers, antidepressants and blood pressure drugs are among 80 medical products that have been put on a “price concessions” list by the Pharmaceutical Services Negotiating Committee, which supplies NHS pharmacies - up from 35 in October.
The list features drugs for which the Department of Health has agreed to pay over the odds in order to prevent shortages.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Ash Soni, president of the Royal Pharmaceutical Society, gave the example of anti-inflammatory naproxen, which he said was “completely out of stock” and could only be purchased at a cost of £6.49 a box - a £2 hike on the price last agreed by the NHS, reports the BBC.
The Independent notes that a “similar spike in 2017” saw the number of concessions reach a high of 91 and ultimately cost the NHS an extra £315m.
As the current crisis grows, some pharmacists are sending patients back to their GPs to “ask for a different medicine or dosage”, while others are “giving patients some of their prescription and sending them away with an IOU note for the rest”, adds the BBC.
Other medicines on the list include the 40mg dosage of furosemide, used to treat high blood pressure and other cardiovascular problems, which is the 23rd most commonly prescribed drug in England.
There are also supply problems for the 20mg and 40mg doses of fluoxetine, used to treat depression, and the 20mg and 40mg doses of propranolol, a common beta-blocker used to treatment of anxiety.
Topiramate, an anticonvulsant that helps control seizures brought on by epilepsy, has been granted a price concession in both its 50mg and 100mg forms, as has the 1mg, 2mg, 3mg and 4mg doses of antipsychotic drug risperidone.
Gareth Jones of the National Pharmacy Association told the BBC that uncertainty over Brexit appears to be a “significant factor” in the shortages. He advised that patients should “order medicines in advance” to “give the pharmacist more time to deal with it”.
Martin Sawer, executive director of the Healthcare Distribution Association, suggested that stockpiling by manufacturers could be affecting supplies.
“Some businesses could be speculating on Brexit. That’s the nature of the market,” he said.
The Daily Express reports that “increased global demand, cost of raw materials, new regulatory requirements” have also been cited as factors for driving up costs, along with fluctuations in exchange rates.
And an NHS push to drive down the prices that it agrees for drugs has “made the UK less attractive to manufacturers”, the newspaper adds.
Meanwhile, former Liberal Democrat MP Sandra Gidley argues that blaming Brexit for dwindling supplies is a red herring, telling the BBC Radio 4’s Today programme that shortages “have been a problem for some years”.
“The situation with Brexit is that the Government have recognised that there could be potential supply problems and they have been asking manufacturers to keep in a buffer stock so that if there are freight problems, trouble with customs, patients will still get their drugs,” Gidley said.
“Unfortunately, what’s been happening on social media over Christmas is that people have been putting two and two together and assuming that this is because of Brexit.”
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Will California's EV mandate survive Trump, SCOTUS challenge?
Today's Big Question The Golden State's climate goal faces big obstacles
By Joel Mathis, The Week US Published
-
'Underneath the noise, however, there’s an existential crisis'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
2024: the year of distrust in science
In the Spotlight Science and politics do not seem to mix
By Devika Rao, The Week US Published
-
Will Starmer's Brexit reset work?
Today's Big Question PM will have to tread a fine line to keep Leavers on side as leaks suggest EU's 'tough red lines' in trade talks next year
By The Week UK Published
-
'Drug epidemics are often cyclical'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
John Prescott: was he Labour's last link to the working class?
Today's Big Quesiton 'A total one-off': tributes have poured in for the former deputy PM and trade unionist
By Harriet Marsden, The Week UK Published
-
Last hopes for justice for UK's nuclear test veterans
Under the Radar Thousands of ex-service personnel say their lives have been blighted by aggressive cancers and genetic mutations
By Sorcha Bradley, The Week UK Published
-
Will Donald Trump wreck the Brexit deal?
Today's Big Question President-elect's victory could help UK's reset with the EU, but a free-trade agreement with the US to dodge his threatened tariffs could hinder it
By Harriet Marsden, The Week UK Published
-
What is the next Tory leader up against?
Today's Big Question Kemi Badenoch or Robert Jenrick will have to unify warring factions and win back disillusioned voters – without alienating the centre ground
By Harriet Marsden, The Week UK Published
-
What is Lammy hoping to achieve in China?
Today's Big Question Foreign secretary heads to Beijing as Labour seeks cooperation on global challenges and courts opportunities for trade and investment
By Harriet Marsden, The Week UK Published
-
Why does Donald Trump want to free the founder of an online black market?
Today's Big Question Ross Ulbricht was sentenced to life in prison for creating the Silk Road market
By Justin Klawans, The Week US Published